English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  We investigated whether different sampling time‐points within one day would influence epidermal growth factor receptor mutation ( EGFRm ) status in plasma and evaluated the clinical outcomes according to the quantity analysis of  EGFRm  in circulating tumor  DNA  ( ctDNA ) in non‐small‐cell lung cancer ( NSCLC ).    Methods   EGFR‐tyrosine kinase inhibitor  naïve advanced  NSCLC  patients who carried  EGFR m in both tissues and ct DNA  were enrolled in this study. Plasma samples were collected at three time‐points within one day (at 8 am, 11 am and 2 pm) for  EGFR m analysis by droplet digital  PCR .    Results  Twenty‐two advanced  NSCLC  patients were enrolled in the study. In a total of 66 blood specimens, the median  EGFR m frequency was 7.13% (range 0–35.09%), and among them six specimens had less than 1.0%  EGFRm  frequency. Moreover, one time‐point blood specimen did not display any  EGFR m, even by droplet digital  PCR . The frequency of  EGFR m changed dynamically across different time‐points within one day, but the differences were not significant ( P  = 0.557). We observed that patients with a relatively high frequency of  EGFR m (>6.76%) had a better response to gefitinib ( P  = 0.024).    Conclusion  The release of  ctDNA  maybe a temporal heterogenous process. The different sampling time‐points within one day did not seem to influence  EGFR m status in  ctDNA . The relative  EGFR m frequency in  ctDNA  could predict a benefit of  EGFR ‐ tyrosine kinase inhibitor  treatment for advanced  NSCLC patients .

thoracic cancer

Analyzing epidermal growth factor receptor mutation status changes in advanced non‐small‐cell lung cancer at different sampling time‐points of blood within one day